[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"marginal-zone-lymphoma-mzl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:marginal-zone-lymphoma-mzl":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,87,117,144,169,180,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053791","registry-platform-hematologic-malignancies-rubin---extension-of-tumor-registry-lymphatic-neoplasms-100053791",false,"NCT06043011","Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","RUBIN","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed diagnosis of the respective NHL\n* If patient is alive: signed written informed consent\n\n  * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.\n  * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.\n\nExclusion Criteria:\n\n* No systemic therapy for respective lymphoid malignancy.","ALL","18 Years",{"count":20,"type":21},2950,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.",[26,27,28,29,30,31],"Chronic Lymphocytic Leukemia (CLL)","Diffuse Large B-cell Lymphoma (DLBCL)","Follicular Lymphoma (FL)","Mantle Cell Lymphoma (MCL)","Marginal Zone Lymphoma (MZL)","Waldenström's Macroglobulinemia (WM)",[33],"non-Hodgkin lymphoma (NHL)","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2023-09-27",{"date":42,"type":21},"2033-12",{"name":44,"class":45},"iOMEDICO AG","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100449326","phase-1-a-study-of-nx-5948-in-adults-with-relapsedrefractory-b-cell-malignancies-100449326","NCT05131022","A Study of NX-5948 in Adults With Relapsed\u002FRefractory B-cell Malignancies","A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\u002FRefractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years\n* Patients in Phase 1a (Dose Escalation) must have histologically confirmed R\u002FR CLL, SLL, DLBCL (subgroups include Richter-transformed DLBCL, germinal center B-cell type, activated B-cell type, high-grade B-cell lymphoma with MYC and BCL-2 and\u002For BCL-6 rearrangements, high-grade B-cell lymphomas NOS), FL, MCL, MZL (subtypes include EMZL, MALT, NMZL, SMZL), WM, or PCNSL.\n* Patients in Phase 1a must meet the following:\n\n  o For non-PCNSL indications, received at least 2 prior lines of therapy and have no other available therapies known to provide clinical benefit. For PCNSL, received at least 1 prior line of therapy\n* Patients in Phase 1b (Safety and Cohort Expansion) must have 1 of the following histologically documented B-cell malignancies, must meet criteria for systemic treatment, and must have received prior therapies and\u002For molecular features based on details described for each cohort: CLL or SLL, DLBCL, MCL, FL, MZL, WM, or PCNSL\u002FSCNSL.\n* Measurable disease per response criteria specific to the malignancy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0-2 for patients with PCNSL and secondary CNS involvement).\n* Adequate organ and bone marrow function\n\nKey Exclusion Criteria:\n\n* Known or suspected active prolymphocytic leukemia or Richter's transformation to Hodgkin's lymphoma prior to study enrollment\n* Prior treatment for the indication under study for anti-cancer intent that includes:\n\n  1. Radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation).\n  2. Prior systemic chemotherapy within 2 weeks of planned start of study drug.\n  3. Prior monoclonal antibody therapy within 4 weeks of planned start of study drug, except for patients enrolling in Cohort 16 (CLL with secondary wAIHA) where a 16-week washout period is required.\n  4. Prior small molecule therapy within 2 weeks or 5 half-lives (whichever is shorter) of planned start of study drug.\n  5. Autologous or allogeneic stem cell transplant within 100 days prior to planned start of study drug.\n  6. Chimeric antigen receptor (CAR) T-cell therapy within 100 days prior to start of study drug (within 60 days prior to start of study drug for Phase 1b).\n  7. Use of systemic corticosteroids outside of dosing limits described below and within 7 days prior to initiation of study treatment excepting those used as prophylaxis for radio diagnostic contrast. Patients with PCNSL\u002FSCNSL: no greater than 40 mg\u002Fday prednisone, or equivalent. Patients with PCNSL\u002FSCNSL using greater than 20 mg\u002Fday prednisone, or equivalent, must be clinically stable at that dose for 7 days. All other diagnoses: no greater than 20 mg\u002Fday prednisone or equivalent.\n  8. Use of systemic immunosuppressive drugs other than systemic corticosteroids for any medical condition within 60 days prior to first dose of study drug\n  9. Previously treated with a BTK degrader\n* Active, uncontrolled autoimmune hemolytic anemia (except for patients enrolling in Cohort 16) or active, uncontrolled autoimmune thrombocytopenia.\n* Patient has any of the following within 6 months of planned start of study drug:\n\n  1. Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, or placement of a coronary arterial stent\n  2. Uncontrolled atrial fibrillation or other clinically significant arrhythmias, conduction abnormalities, or New York Heart Association (NYHA) class III or IV heart failure\n  3. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), stroke, or intracranial hemorrhage\n  4. Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, severe congenital heart disease, or persistent uncontrolled hypertension defined as systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg despite optimal medical management)\n* Bleeding diathesis, or other known risk for acute blood loss.\n* History of Grade ≥ 2 hemorrhage within 28 days of planned start of study drug.\n* Active known concurrent malignancy or malignancy other than the one under study within the past 3 years. (Exceptions include, but are not limited to, patients with more recent history of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast may enroll if they have undergone curative therapy and have no evidence of disease).",{"count":55,"type":21},572,"INTERVENTIONAL",[58],"PHASE1","This is a first-in-human Phase 1a\u002F1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.",[26,61,62,28,29,30,63,64,65],"Small Lymphocytic Lymphoma (SLL)","Diffuse Large B Cell Lymphoma (DLBCL)","Waldenstrom Macroglobulinemia (WM)","Primary Central Nervous System Lymphoma (PCNSL)","Secondary Central Nervous System Lymphoma (SCNSL)",[67,68,69,70,71,72,73,74,75,76],"BTK Degrader","BTK Inhibitor","B-Cell Malignancy","Lymphoma","C481","C481S","Bruton's Tyrosine Kinase","NX-5948","Targeted Protein Degradation","Chimeric Targeting Molecule (CTM)","2026-06-30",{"date":79,"type":38},"2026-07-02",{"date":81,"type":38},"2022-04-13",{"date":83,"type":21},"2028-01",{"name":85,"class":45},"Nurix Therapeutics, Inc.",62,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":56,"phases":96,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100591414","phase-1-dose-determining-study-of-exs73565-in-participants-with-relapsed-or-refractory-b-cell-malignancies-100591414","NCT06980116","Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies","A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia.\n* Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Known central nervous system (CNS) malignancy or primary CNS lymphoma.\n* Concurrent active or previous malignancy (other than the primary lymphoma\u002FCLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval.\n* Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment.",{"count":95,"type":21},85,[58],"The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed\u002Frefractory B-cell malignancies.",[99,100,28,30,29,101,102],"Relapsed or Refractory B-cell Malignancies","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)","Diffuse-large B-cell Lymphoma (DLBCL)","Waldenstrom's Macroglobulinemia (WM)",[104,105,28,30,29,101,102,106],"B-cell Malignancies","Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL)","MALT1","2026-06-09",{"date":109,"type":38},"2026-06-11",{"date":111,"type":38},"2025-03-31",{"date":113,"type":21},"2028-12",{"name":115,"class":45},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",9,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":56,"phases":126,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100426218","phase-1-a-study-of-nx-2127-in-adults-with-relapsedrefractory-b-cell-malignancies-100426218","NCT04830137","A Study of NX-2127 in Adults With Relapsed\u002FRefractory B-cell Malignancies","A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed\u002FRefractory B-cell Malignancies","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age\n* Patients must have measurable disease per disease-specific response criteria\n* Patients with indolent forms of NHL must meet the criteria requiring systemic treatment (i.e., iwCLL, IWG, Lugano Classification of Lymphoma response criteria, or International PCNSL Collaborative Group response criteria)\n* Patients with transformed lymphoma are eligible for the study with the exception of those detailed in Exclusion Criteria #1: Prolymphocytic leukemia, MCL with blastoid histology, MCL with pleomorphic morphology, or MCL with known TP53 mutation\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (non-PCNSL indications) or 0 - 2 (PCNSL patients)\n* Adequate organ and bone marrow function\n* Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol\n\nInclusion Criteria for Patients in Phase 1a:\n\n* Have histologically confirmed R\u002FR CLL, SLL, WM, MCL, and MZL, FL, DLBCL, or PCNSL\n* Received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and have no other therapies known to provide clinical benefit\n* Must require systemic therapy\n\nInclusion Criteria for Patients in Phase 1b:\n\n* Must have one of the following histologically documented R\u002FR B-cell malignancies:\n\n  * CLL\u002FSLL whose disease has failed treatment with a BTKi;\n  * MCL whose disease has failed treatment with BTKi and an anti-CD20 mAb-based regimen\n  * FL or MZL whose disease has failed treatment with an anti-CD20 mAb-based regimen; or WM whose disease has failed treatment with a BTKi\n  * PCNSL whose disease failed at least 1 prior line of treatment\n  * DLBCL whose disease has failed treatment with an anti-CD20 mAb-based regimen and either: an anthracycline-based regimen; or an anti-CD19-based regimen, or another\u002F palliative regimen (either progressed post stem cell transplant or transplant-ineligible)\n\nExclusion Criteria:\n\n* Active, uncontrolled autoimmune hemolytic anemia or autoimmune thrombocytopenia\n* History of known\u002Fsuspected other autoimmune disease (exception(s): patients with alopecia, vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism that is clinically euthyroid at screening are allowed.)\n* Unable to swallow capsules or have a condition that may interfere in the delivery, absorption, or metabolism of the study drug\n* Bleeding diathesis, or other known risk for acute blood loss\n* Patients requiring ongoing treatment with warfarin or an equivalent vitamin K antagonist and within 7 days prior to the first dose of study drug\n* Prior radiotherapy within 2 weeks of planned start of study drug (excluding limited palliative radiation)\n* Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, hypothyroidism with adequate replacement therapy, hypopituitarism with adequate replacement therapy, peripheral neuropathy or hematologic parameters meeting inclusion criteria).\n* Active known second malignancy. Exception: patients with non-metastatic, non-melanoma skin cancer are eligible\n* Patient has had major surgery (e.g. requiring general anesthesia) within 4 weeks before the planned first dose of study drug\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: patients with well-controlled HIV (e.g., CD4 \\> 350\u002Fmm3 and undetectable viral load) are eligible.\n* Current active liver disease from any cause\n* Active viral reactivation (e.g., CMV or EBV)\n* Use of systemic corticosteroids exceeding 20 mg\u002Fday prednisone (or equivalent) for non-PCNSL indications within 15 days prior to the planned start of study drug. PCNSL patients may not exceed corticosteroid doses of 40 mg\u002Fday prednisone (or equivalent) and should be on a stable or decreasing dose for 7 days prior to planned study start.\n* Use of non-steroidal immunosuppressive drugs within 30 days prior to start of the study\n* Clinically significant, uncontrolled cardiac, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug\n* Administration of any strong cytochrome P450 3A (CYP3A) inducers or inhibitors for 14 days prior to the first dose of study drug, and any P-glycoprotein inhibitors (for 2 days) or moderate inducers of CYP3A for 7 days",{"count":125,"type":21},248,[58],"This is a first-in-human Phase 1a\u002F1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.",[26,61,63,29,30,28,27,64],[67,68,130,70,131,132,133,73,134,75,76,71,72],"B-cell Malignancy","IMiD","Lenalidomide","Pomalidomide","NX-2127","2026-03-18",{"date":137,"type":38},"2026-03-20",{"date":139,"type":38},"2021-05-05",{"date":141,"type":21},"2027-05",{"name":85,"class":45},16,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":56,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100602318","phase-1-this-is-a-phase-1-study-to-evaluate-the-safety-of-ltz-301-in-patients-with-non-hodgkin-lymphoma-100602318","NCT07121946","This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma","A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed\u002FRefractory Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Relapsed or refractory to at least 2 prior systemic treatment regimens\n* At least 1 bi-dimensionally measurable lesion (≥ 1.5 cm) in longest dimension\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Adequate bone marrow, cardiac, pulmonary, renal, and hepatic function\n\nExclusion Criteria:\n\n* CLL, or Richters transformation\n* Prior solid organ transplant\n* Prior allogeneic stem cell transplant\n* ASCT within 100 days prior to the first LTZ-301 administration\n* Prior CAR-T within 60 days prior to the first LTZ-301 administration\n* Current central nervous system (CNS) lymphoma\n* Known history of human immunodeficiency virus (HIV) seropositivity\n* Active autoimmune disease\n* History of clinically significant cardiovascular disease\n* symptomatic deep vein thrombosis (DVT) within 3 months of enrollment\n* History of other malignancy within 3 years prior to screening",{"count":152,"type":21},42,[58],"This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma",[156,157,29,158,30],"Non-Hodgkin Lymphoma Refractory\u002F Relapsed","DLBCL - Diffuse Large B Cell Lymphoma","Follicular Lymphoma ( FL)","2026-02-06",{"date":161,"type":38},"2026-02-10",{"date":163,"type":38},"2026-01-29",{"date":165,"type":21},"2028-02",{"name":167,"class":45},"LTZ Therapeutics, Inc.",5,{"id":170,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":172,"keywords":173,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":178,"leadSponsor":179,"locationsCount":46},"100519397",{"count":20,"type":21},[26,27,28,29,30,31],[33],"2026-01-26",{"date":176,"type":38},"2026-01-28",{"date":40,"type":38},{"date":42,"type":21},{"name":44,"class":45},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":56,"phases":189,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":46},"100621572","phase-2-orelabrutinib-as-consolidation-and-maintenance-therapy-in-treatment-nave-mzl-100621572","NCT07372365","Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.","Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve Marginal Zone Lymphoma: A Study of Efficacy and Safety.","Inclusion Criteria:\n\n1. Histologically confirmed CD20-positive marginal zone lymphoma (MZL) that has not received systemic therapy.\n2. MZL that has progressed or relapsed after prior local therapy (local therapy includes surgery, radiotherapy, Helicobacter pylori eradication, and hepatitis C treatment) or is not amenable to local therapy.\n3. Age ≥18 years.\n4. Presence of an indication for treatment as determined by the investigator or patient's willingness to receive treatment.\n5. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2.\n6. Adequate organ function as defined below:\n\n   * Hematology: Hemoglobin (HB) ≥60 g\u002FL, platelets (PLT) ≥50×10⁹\u002FL, neutrophils (NE) ≥1.0×10⁹\u002FL (Note: Subjects with cytopenia due to lymphoma bone marrow involvement are not restricted by this criterion).\n   * Cardiac: Left ventricular ejection fraction (LVEF) ≥50% as determined by echocardiogram.\n   * Renal: Creatinine ≤1.5×upper limit of normal (ULN) or creatinine clearance ≥30 ml\u002Fmin.\n   * Hepatic: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN.\n7. Women of childbearing potential must have a negative pregnancy test. Both male and female patients must agree to use effective contraception during the treatment period and for 2 years thereafter.\n8. Life expectancy of more than 3 months.\n9. Voluntary provision of written informed consent.\n\nExclusion Criteria:\n\n1. Underwent major surgery or severe trauma within 2 weeks prior to enrollment, or has not yet recovered from significant adverse effects.\n2. Has other malignancies currently or within the past 3 years, excluding those that have been cured (such as basal or squamous cell carcinoma of the skin, superficial bladder cancer, prostatic intraepithelial neoplasia, and cervical carcinoma in situ).\n3. Has a history of stroke or intracranial hemorrhage within the past 3 months.\n4. Requires anticoagulation with warfarin or equivalent vitamin K antagonist.\n5. Has evidence of any comorbidities or medical conditions that may interfere with the conduct of the study or place the patient at significant risk, including but not limited to severe cardiovascular disease (e.g., New York Heart Association class III or IV heart disease, myocardial infarction within the past 6 months, unstable arrhythmia, or unstable angina) and\u002For severe pulmonary disease (e.g., severe obstructive pulmonary disease and a history of symptomatic bronchospasm).\n6. Is infected with human immunodeficiency virus, or has uncontrollable active hepatitis C virus or hepatitis B virus infection.\n7. Has uncontrollable active infection.\n8. Is pregnant or breastfeeding.\n9. Has any life-threatening disease, medical condition, or organ dysfunction that may jeopardize the safety of the patient, as determined by the investigator.\n10. Has any condition that may interfere with the absorption or metabolism of orelabrutinib or place the study results at unnecessary risk.\n11. Has central nervous system involvement by marginal zone lymphoma or evidence of disease transformation.\n12. Has any condition that the investigator judges may interfere with the patient's full participation in the study; any condition that poses significant risk to the patient; or any condition that may interfere with the interpretation of study data.",{"count":188,"type":21},23,[190],"PHASE2","This study aims to explore a new treatment approach for patients with treatment-naive Marginal Zone Lymphoma (MZL). MZL is a type of slow-growing lymphoma that often affects older adults. The current standard treatment involves chemotherapy, but it can have significant side effects and may not always provide long-term benefits. This study investigates a treatment strategy that combines a limited course of chemotherapy (R-CHOP) followed by consolidation and maintenance therapy with a targeted drug called Orelabrutinib.\n\nPatients will undergo a series of tests to determine eligibility for the study. These tests include blood work, imaging studies, and assessments of overall health. Eligible participants will receive a standard chemotherapy regimen called R-CHOP for three cycles. After this, the response to treatment will be evaluated. Participants who show a good response will then receive three cycles of consolidation therapy with Orelabrutinib and Rituximab (OR). Those who continue to respond well will enter a maintenance phase with Orelabrutinib for up to two years. Throughout the study, participants will be closely monitored for treatment response and any side effects. Regular check-ups, blood tests, and imaging studies will be conducted to assess the effectiveness and safety of the treatment.\n\nThis study is an important step towards finding better treatment options for MZL patients. It is hoped that through this research, the quality of life and outcomes for those affected by this disease can be improved.",[30],"2026-01-19",{"date":176,"type":38},{"date":196,"type":38},"2025-10-24",{"date":198,"type":21},"2030-10-01",{"name":200,"class":201},"The First Affiliated Hospital of Soochow University","OTHER",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":212,"studyType":23,"phases":4,"briefSummary":213,"conditions":214,"keywords":219,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":234},"100352496","real-world-data-in-lymphoma-and-survival-in-adults-100352496","NCT03869619","REal World Data in LYmphoma and Survival in Adults","REAL WORLD DATA IN LYMPHOMA AND SURVIVAL IN ADULTS","REALYSA","Inclusion Criteria:\n\n* Signature of the consent form for participation in the REALYSA cohort\n* Aged over 18 at the time of inclusion\n* Diagnosed with lymphoma in the last 6 months (180 days)\n* Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma\n\nExclusion Criteria:\n\n* Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination)\n* Documented HIV infection\n* Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:\n\n  * Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma\n  * Hairy cell leukemia and variant\n  * Lymphoplasmacytic lymphoma\n  * Waldenström macroglobulinemia\n  * Primary DLBCL of the central nervous system (CNS)\n  * T-cell large granular lymphocytic leukemia\n  * Chronic lymphoproliferative disorder of NK cells\n  * Mycosis fungoides\n  * Sézary syndrome\n  * Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists)\n  * Post-transplant lymphoproliferative disorders (PTLD)",{"count":211,"type":21},6000,"9 Years","REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.\n\nREALYSA is a platform perfectly set up to\n\n* Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)…\n* Document treatment effectiveness in real life and observance\n* Address socio-economical questions",[215,28,29,30,216,217,218],"Diffuse Large B Lymphoma (DLBCL)","T-cell Lymphoma (T-NHL)","Hodgkin's Lymphoma (HL)","Burkitt Lymphoma (BL))",[220,221,222,223,224],"lymphoma","real life","cohort","epidemiology","PRO","2021-06-25",{"date":227,"type":38},"2021-06-28",{"date":229,"type":38},"2018-11-14",{"date":231,"type":21},"2027-11-14",{"name":233,"class":201},"Hospices Civils de Lyon",37]